Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 5Phase 1/2 3Phase NA 2Phase EARLY_PHASE1 1Phase 3 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 6INDUSTRY 3NIH 1INDIV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Gastrointestinal 2Thoracic 1Plasma cell 1Gynecologic 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 438Neoplasms 363Breast Neoplasms 260Colorectal Neoplasms 243Neoplasm Metastasis 213Melanoma 209Leukemia, Myeloid, Acute 188Multiple Myeloma 187Pancreatic Neoplasms 181Ovarian Neoplasms 178Recurrence 173Prostatic Neoplasms 161Lymphoma, Non-Hodgkin 142Stomach Neoplasms 133Squamous Cell Carcinoma of Head and Neck 127Lung Neoplasms 125Lymphoma 121Carcinoma, Hepatocellular 117Carcinoma, Renal Cell 102Triple Negative Breast Neoplasms 100Leukemia, Lymphocytic, Chronic, B-Cell 99Glioblastoma 97Leukemia 93Advanced Solid Tumor 92Small Cell Lung Carcinoma 91Lymphoma, Large B-Cell, Diffuse 90Head and Neck Neoplasms 87Advanced Solid Tumors 84Endometrial Neoplasms 79Myelodysplastic Syndromes 78

Interventions

resiquimod 1poly ICLC 1envafolimab 1enasidenib 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × Chondrosarcoma × Clear all
NCT05448820 2023-09-21

YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma

Tracon Pharmaceuticals Inc.

Phase 1/2 Unknown
15 enrolled
Sarcoma

Diabetes Mellitus, Insulin-Dependent, 12, Chondrosarcoma, Sarcoma

NCT02273739 2021-02-23

Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation

Celgene

Phase 1/2 Completed
21 enrolled 33 charts
CNSGastrointestinalSarcoma

Chondrosarcoma, Glioma, Immunoblastic Lymphadenopathy, Cholangiocarcinoma

NCT00948961 2016-06-27

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Celldex Therapeutics

Phase 1/2 Completed
70 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡